or Try an Advanced Search...

    Technical Analysis for TLX - Telix Pharmaceuticals Ltd  

    Grade Last Price % Change Price Change
    B 22.580 1.71% 0.380
    TLX closed up 1.71 percent on Friday, November 22, 2024, on 45 percent of normal volume.
    5 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Down
    Historical TLX trend table...
    Date Alert Name Type % Chg
    Crossed Above 20 DMA Bullish 0.00%
    Inside Day Range Contraction 0.00%
    Gapped Up Strength 0.00%
    Fell Below 20 DMA Bearish 1.71%
    Gapped Up Strength -1.66%
    MACD Bearish Signal Line Cross Bearish -1.91%
    Pocket Pivot Bullish Swing Setup -1.91%
    Outside Day Range Expansion -1.91%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.88%
    NR7 Range Contraction -0.88%
    Older End-of-Day Signals for TLX ...

       Recent Intraday Alerts

    Alert Time
    Possible Inside Day 3 days ago
    10 DMA Resistance 3 days ago
    Up 3% 3 days ago
    Gap Up Partially Closed 3 days ago
    Gapped Up (Partial) 3 days ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    TLX Chart by TradingView
    Basic chart:

    Profile

    Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company. The Company is focused on development and commercialization of diagnostic and therapeutic products based on radiopharmaceuticals, or molecularly-targeted radiation (MTR). MTR is a novel therapeutic approach that selectively delivers radiation to cells that exhibit certain molecular profiles or targets that may be indicative of cancer. The Company's MTR products such as TLX-250 diagnosis and treatment of renal (kidney), TLX-591 treatment of metastatic castrate-resistant prostate cancer, and TLX-101 treatment of glioblastoma (brain cancer).
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Natural Sciences Medicine Pharmaceutical Radio Cancer Drugs Pharmaceuticals Biopharmaceutical Profile Therapeutic Product Therapeutic Products Radiation Brain Cancer Prostate Cancer Radiation Therapy Radiopharmaceuticals Glioblastoma Radioactivity Radiopharmaceutical

    Is TLX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 18 Telix to Add FAP-Targeting Candidates to Theranostic Pipeline
    Nov 13 Telix ADSs Commence Trading on Nasdaq
    Nov 13 Telix and Eckert & Ziegler to Partner on Actinium-225 Production Technology
    Nov 3 Telix Welcomes CMS Decision to Improve Payments for Diagnostic Radiopharmaceuticals
    Oct 30 Telix Partners with Subtle Medical on AI-Enabled SubtlePET™ Software for Faster PET Imaging with Illuccix®
    Oct 23 FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent
    Oct 22 Telix Spins Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals
    Oct 17 Telix Files Form 20-F Registration Statement for Nasdaq ADS
    Oct 17 Telix Q3 2024 Business Update - Quarterly Revenue Exceeds AU$200M
    Oct 7 Australian TGA Approves Additional Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy
    See more TLX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 23.99
    52 Week Low 9.06
    Average Volume 1,041,635
    200-Day Moving Average 17.190
    50-Day Moving Average 21.298
    20-Day Moving Average 22.406
    10-Day Moving Average 22.914
    Average True Range 0.751
    RSI (14) 54.95
    ADX 13.94
    +DI 20.919
    -DI 22.864
    Chandelier Exit (Long, 3 ATRs) 21.736
    Chandelier Exit (Short, 3 ATRs) 22.864
    Upper Bollinger Bands 24.024
    Lower Bollinger Band 20.787
    Percent B (%b) 0.55
    BandWidth 14.446
    MACD Line 0.448
    MACD Signal Line 0.554
    MACD Histogram -0.1055
    Fundamentals Value
    Market Cap 6.23 Billion
    Num Shares 276 Million
    EPS -0.09
    Price-to-Earnings (P/E) Ratio -253.71
    Price-to-Sales 214.62
    Price-to-Book 14.38
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 23.330
    Resistance 3 (R3) 23.363 23.147 23.205
    Resistance 2 (R2) 23.147 22.956 23.130 23.163
    Resistance 1 (R1) 22.863 22.838 23.005 22.830 23.122
    Pivot Point 22.647 22.647 22.718 22.630 22.647
    Support 1 (S1) 22.363 22.456 22.505 22.330 22.038
    Support 2 (S2) 22.147 22.338 22.130 21.997
    Support 3 (S3) 21.863 22.147 21.955
    Support 4 (S4) 21.830